GlaxoSmithKline is investing $100 million in its manufacturing site in Hamilton, MT to expand the production capacity of key components of the adjuvant system used in several of GSK’s vaccines, including SHINGRIX, which was approved by the U.S. FDA in October 2017.

The Hamilton vaccines facility currently manufactures components of GSK’s essential adjuvant technologies, which this investment will expand further. GSK’s adjuvant systems help achieve a stronger immune response.

“For more than a decade, our Hamilton facility has supported GSK’s adjuvant system development program,” said Jack Bailey, president, US Pharmaceuticals, GSK. “By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including SHINGRIX.”

GSK is investing in creating high-quality jobs in areas like R&D and manufacturing. The Hamilton site expansion is expected to add a combination of temporary construction and contracting jobs, as well as new permanent positions, including scientists, engineers and manufacturing and quality professionals.  

“Thanks to the bi-partisan support of Governor Steve Bullock and the congressional delegation – Sens. Jon Tester and Steve Daines and Rep. Greg Gianforte – Montana is emerging as a hub for the biotechnology industry,” said Bailey. “GSK is grateful for their leadership and the opportunity they have given us to create new jobs and expand our footprint in the state.”

Hamilton is one of nine GSK manufacturing sites in the U.S., and 86 sites globally, that produce a variety of prescription medicines, vaccines and consumer healthcare products.